

Fax completed form to: 1-866-868-0858

Questions, please call: 1-866-316-6049

**TODAY'S OPTIONS<sup>®</sup>**

**Important Information About Prescription Drug Coverage**

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Pegasys<sup>®</sup> (Peginterferon Alpha 2-a injection): Prior Authorization Request Form: Please respond.

- Please complete the attached Pegasys<sup>®</sup> (Peginterferon Alpha 2-a injection) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

**Information about this drug**

**Pegasys<sup>®</sup>(Peginterferon Alpha 2-a injection)**

Alpha interferons, including Pegasys<sup>®</sup>, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Pegasys<sup>®</sup> should be used cautiously in patients with a CrCl < 50ml/min, baseline neutrophil counts < 1500cells/mm<sup>3</sup>, with baseline platelet counts < 90,000cells/mm<sup>3</sup> or baseline hemoglobin < 10 g/dL.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

MemberHealth, LLC, PO Box 391197, Solon OH 44139-3911

Last Updated: 12/13/2007

M0018\_TO\_PaTemp\_1107 CMS 11/28/07 H3333/H5421

# Prior Authorization Request Form

Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Pegasys®(Peginterferon Alpha 2-a injection) Criteria

- Please indicate Pegasys® dispensing location:  
 the pharmacy  
 the physician's supply, incident to a physician's service  
 other: \_\_\_\_\_
- Please indicate the patient's diagnosis. Select or specify the correct ICD-9 code. This question must be completed  
 Chronic hepatitis B (HBeAg either positive or negative) in adults who have compensated liver disease and evidence of viral replication (detectable levels of HBV DNA) and liver inflammation (ATL > 2xULN)  
 Chronic hepatitis C virus infection in adults who have compensated liver disease and have not been previously treated with interferon alpha (ICD-9: 070).  
 Other (ICD-9 and diagnosis): \_\_\_\_\_
- Is the prescribing physician a gastroenterologist, infectious disease specialist, hepatologist, transplant surgeon or has one been consulted?  
 Yes  No
- Has the patient had a liver biopsy (unless contraindicated) demonstrating fibrosis and inflammation?  
 Yes  No
- Does the patient have any contraindications to the use of Pegasys® (e.g., hypersensitivity to peginterferon alfa-2a or its components, autoimmune hepatitis, hepatic decompensation in cirrhotic patients (Child-Pugh score greater than 6 (class B and C)) before or during treatment, hepatic decompensation in cirrhotic chronic hepatitis C patients (Child-Pugh score greater than or equal to 6) coinfecting with HIV before or during treatment, hypersensitivity to peginterferon alfa-2b or any of the components)?  
 Yes  No

Medical Justification: (Attach additional page if necessary): \_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_